Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditions

Journal of the National Cancer Institute

Volumn 99, Issue 13, 2007, Pages 986-987

  Woo, Sook Bin ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE CANCER; BONE NECROSIS; BONE TURNOVER; CANCER SURVIVAL; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; JAW DISEASE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MORBIDITY; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOMYELITIS; OSTEOPOROSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; TOOTH INFECTION; AGED; BONE; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; INFLAMMATION; JAW; NEOPLASM; NOTE; PATHOLOGY;

AGED; BONE AND BONES; DIPHOSPHONATES; HUMANS; INFLAMMATION; JAW; JAW DISEASES; NEOPLASMS; OSTEONECROSIS; PREVALENCE;

EID: 34447252822     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm029     Document Type: Editorial

References (13)

1. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
2. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200.
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
5. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24:945-52.
6. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.
7. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 2006;134:620-3.
8. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102; discussion 99-102.
9. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-7.
10. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-53.
11. Wilkinson GS, Kuo Y, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and infl ammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-24.
12. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23.
13. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41.